• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$9.85
▼ -0.31 (-3.05%)

This chart shows the closing price for EVTCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evotec Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVTCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVTCY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Evotec in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $9.85.

This chart shows the closing price for EVTCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Evotec. This rating has held steady since August 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/16/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
5/11/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
4/22/2021Deutsche Bank AktiengesellschaftReiterated RatingHold
3/5/2021CitigroupDowngradeBuy ➝ Neutral
1/28/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
1/19/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
11/20/2020Royal Bank of CanadaReiterated RatingOutperform
9/10/2020Royal Bank of CanadaInitiated CoverageOutperform
9/1/2020CitigroupInitiated CoverageBuy
3/12/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
8/21/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/10/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
7/27/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy
(Data available from 1/31/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/30/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Evotec logo
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Read More

Today's Range

Now: $9.85
Low: $9.81
High: $10.06

50 Day Range

MA: $8.74
Low: $7.80
High: $10.34

52 Week Range

Now: $9.85
Low: $14.22
High: $26.57

Volume

6,946 shs

Average Volume

2,407 shs

Market Capitalization

$3.25 billion

P/E Ratio

24.02

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Evotec?

The following Wall Street sell-side analysts have issued reports on Evotec in the last twelve months:
View the latest analyst ratings for EVTCY.

What is the current price target for Evotec?

0 Wall Street analysts have set twelve-month price targets for Evotec in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Evotec in the next year.
View the latest price targets for EVTCY.

What is the current consensus analyst rating for Evotec?

Evotec currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EVTCY.

What other companies compete with Evotec?

How do I contact Evotec's investor relations team?

Evotec's physical mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The company's listed phone number is (494) 056-0810 and its investor relations email address is [email protected] The official website for Evotec is www.evotec.com. Learn More about contacing Evotec investor relations.